Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 13/20 | 0.80 |
| ▸ | USP47 | Q96K76 | 6/20 | 0.80 |
| ▸ | USP10 | Q14694 | 1/20 | 0.80 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493045 | 0.89 | USP7 (1.00) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680945 | 0.89 | USP7 (1.00) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2681306 | 0.88 | USP7 (0.77) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680694 | 0.78 | USP7 (0.80) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL2681097 | 0.76 | USP7 (0.58) | USP7USP47USP10PADI4 | |
| SCHEMBL28903536 | 0.76 | USP7 (0.60) | USP7USP47USP10ATMTDP1 | |
| SCHEMBL3715157 | 0.76 | USP7 (0.60) | USP7USP47USP10ATMTDP1 | |
| SCHEMBL1455298 | 0.75 | USP47 (0.65) | USP7USP47USP10PADI4 | |
| SCHEMBL2681153 | 0.75 | USP7 (0.57) | USP7USP47USP10 | |
| SCHEMBL2680671 | 0.74 | HSPB1 (0.56) | USP7USP47USP10ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885USP47 315/4885USP10 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.